Last Price
3.02
Today's Change
0.00 (0.00%)
Day's Change
2.77 - 3.07
Trading Volume
381,065
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Ms. Jennifer L. Good Ms. Jennifer L. Good
Full Time Employees: 26 26
IPO Date: 2019-05-07 2019-05-07
CIK: 0001563880 0001563880
ISIN: US89532M1018 US89532M1018
CUSIP: 89532M101 89532M101
Beta: 0.97 0.97
Last Dividend: 0.00 0.00
Dcf Diff: 2.71 2.71
Dcf: 0.31 0.31
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.